관상동맥중재술 전후 주요 항협심증 약제로서의 베타차단제와 칼슘채널차단제: 처방패턴 및 임상결과에 미치는 영향
Beta Blockers or Calcium Channel Blockers as Primary Antianginal Drug after Percutaneous Coronary Intervention: Prescription Pattern and its association with Clinical Outcome
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Although guideline recommends beta blockers (BBs) as first line antianginal agent and calcium channel blockers (CCBs) as alternatives after percutaneous coronary intervention (PCI), the prescription patterns in real practice are not in accordance with the guideline. We aimed to investigate the prescribing patterns of primary antianginal drug and relating factors in patients who underwent PCI. Methods: Patients who have undergone PCI without myocardial infarction (MI) from November 2012 to June 2014 and followed up at least one year in a tertiary teaching hospital were included. Prescribing patterns of primary antianginal drug before, at the time of, and one year after PCI were described. Factors affecting drug selection, and their relationship with incidence of clinical outcomes defined as MI and repeated PCI, unscheduled admission or visit related with heart problem were analyzed with multivariate logistic regression. Results: A total of 506 patients were included and as primary antianginal drugs, BB, CCB, and both were prescribed in 32.2%, 24.5%, and 17.8% of patients, respectively. Also, neither BB nor CCB was prescribed at the time of PCI in 25.5% of patients. Compared with BB, CCBs were more likely prescribed in patients who had hypertension (Odds Ratio, OR 2.18,95% confidence interval, CI 1.16-4.07), use of same class before PCI (OR 7.18, 3.37-15.2) and concomitant angiotensin receptor blocker (ARB) use (OR, 1.92, 95% CI 1.10-3.33). Incidence of clinical outcomes were not significantly greater in patients who prescribed CCB compared with BB at the time of PCI (aOR 1.32, CI 0.65-2.68). Conclusion: This study demonstrated that half of the patients who underwent PCI were prescribed BB. CCB were favored in patients with hypertension, use of same class before PCI, and concomitant ARB use. Significant difference in clinical outcome was not observed between BB and CCB selection as primary antianginal drug.
Abstract
Objective: Although guideline recommends beta blockers (BBs) as first line antianginal agent and calcium channel blockers (CCBs) as alternatives after percutaneous coronary intervention (PCI), the prescription patterns in real practice are not in accordance with the guideline. We aimed to investigate the prescribing patterns of primary antianginal drug and relating factors in patients who underwent PCI. Methods: Patients who have undergone PCI without myocardial infarction (MI) from November 2012 to June 2014 and followed up at least one year in a tertiary teaching hospital were included. Prescribing patterns of primary antianginal drug before, at the time of, and one year after PCI were described. Factors affecting drug selection, and their relationship with incidence of clinical outcomes defined as MI and repeated PCI, unscheduled admission or visit related with heart problem were analyzed with multivariate logistic regression. Results: A total of 506 patients were included and as primary antianginal drugs, BB, CCB, and both were prescribed in 32.2%, 24.5%, and 17.8% of patients, respectively. Also, neither BB nor CCB was prescribed at the time of PCI in 25.5% of patients. Compared with BB, CCBs were more likely prescribed in patients who had hypertension (Odds Ratio, OR 2.18,95% confidence interval, CI 1.16-4.07), use of same class before PCI (OR 7.18, 3.37-15.2) and concomitant angiotensin receptor blocker (ARB) use (OR, 1.92, 95% CI 1.10-3.33). Incidence of clinical outcomes were not significantly greater in patients who prescribed CCB compared with BB at the time of PCI (aOR 1.32, CI 0.65-2.68). Conclusion: This study demonstrated that half of the patients who underwent PCI were prescribed BB. CCB were favored in patients with hypertension, use of same class before PCI, and concomitant ARB use. Significant difference in clinical outcome was not observed between BB and CCB selection as primary antianginal drug.
참고문헌 (15)
- Fihn SD, "2012 ACCF", AHA, AATS, pp.PCNA, SCAI[DOI]
- Abrams J, "Chronic stable angina", N Engl J Med, 352, pp.2524~2533 (2005)
- Kohro T, "Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study", Circ J, 71, pp.1835~1840 (2007)
- Borden WB, "Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention", JAMA, 305, pp.1882~1889 (2011)
- Endo A, "Disparity in the application of guideline-based medical therapy after percutaneous coronary intervention:analysis from the Japanese prospective multicenter registry", Am J Cardiovasc Drugs, 13, pp.103~112 (2013)
- Jiang J, "Current status and influence factors of beta blocker prescription in Chinese patients with stable angina pectoris", Zhonghua Xin Xue Guan Bing Za Zhi, 43, pp.227~233 (2015)
- Freemantle N, "β Blockade after myocardial infarction: systematic review and meta regression analysis", BMJ, 318, pp.1730~1737 (1999)
- Shu de F, "Long-term beta blockers for stable angina: systematic review and meta-analysis", Eur J Prev Cardiol, 19, pp.330~341 (2012)
- Garg P, "Practice patterns and trends in the use of medical therapy in patients undergoing percutaneous coronary intervention in Ontario", J Am Heart Assoc, 3(4), pp.e000882~ (2014)
- James PA, "2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)", JAMA, 311, pp.507~520 (2014)
- Heidenreich PA, "Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina", JAMA, 281, pp.1927~1936 (1999)
- Rehnqvist N, "Effects of metoprolol vs verapamil in patients with stable angina pectoris", Eur Heart J, 17, pp.76~81 (1996)
- Fox KM, "Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group", Eur Heart J, 17, pp.96~103 (1996)
- Von Arnim T, "Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators", J Am Coll Cardiol, 25, pp.231~238 (1995)
- Dwivedi SK, "Silent ischemic interval on exercise test is a predictor of response to drug therapy: a randomized crossover trial of metoprolol versus diltiazem in stable angina", Clin Cardiol, 24, pp.45~49 (2001)